Shares

37 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Apr 05, 2024

SELL
$144.61 - $166.54 $32.8 Million - $37.8 Million
-226,889 Closed
0 $0
Q4 2022

Apr 05, 2024

SELL
$138.31 - $165.87 $3.87 Million - $4.65 Million
-28,010 Reduced 10.99%
226,889 $36.7 Billion
Q3 2022

Apr 05, 2024

SELL
$134.21 - $153.93 $1.3 Million - $1.49 Million
-9,678 Reduced 3.66%
254,899 $34.2 Billion
Q2 2022

Apr 05, 2024

SELL
$137.62 - $174.96 $1.32 Million - $1.68 Million
-9,590 Reduced 3.5%
264,577 $40.5 Billion
Q1 2022

Apr 05, 2024

BUY
$131.98 - $163.75 $31.9 Million - $39.6 Million
242,060 Added 753.92%
274,167 $44.4 Billion
Q4 2021

Apr 05, 2024

SELL
$107.43 - $135.93 $5.04 Million - $6.38 Million
-46,900 Reduced 59.36%
32,107 $4.35 Billion
Q3 2021

Apr 05, 2024

BUY
$106.4 - $120.78 $266,000 - $301,950
2,500 Added 3.27%
79,007 $8.52 Billion
Q2 2021

Apr 05, 2024

BUY
$105.21 - $117.21 $599,697 - $668,097
5,700 Added 8.05%
76,507 $8.62 Billion
Q1 2021

Apr 05, 2024

BUY
$102.3 - $112.62 $3.56 Million - $3.92 Million
34,800 Added 96.65%
70,807 $7.66 Billion
Q4 2020

Apr 05, 2024

SELL
$80.49 - $108.67 $217,323 - $293,409
-2,700 Reduced 6.98%
36,007 $3.86 Billion
Q3 2020

Apr 05, 2024

SELL
$85.91 - $100.83 $197,593 - $231,909
-2,300 Reduced 5.61%
38,707 $3.39 Billion
Q2 2020

Apr 05, 2024

BUY
$73.37 - $98.18 $477,418 - $638,857
6,507 Added 18.86%
41,007 $4.03 Billion
Q1 2020

Apr 05, 2024

SELL
$64.5 - $97.79 $180,600 - $273,812
-2,800 Reduced 7.51%
34,500 $2.63 Billion
Q4 2019

Apr 05, 2024

SELL
$72.13 - $90.25 $2.08 Million - $2.6 Million
-28,800 Reduced 43.57%
37,300 $3.3 Billion
Q3 2019

Apr 05, 2024

BUY
$62.98 - $75.72 $195,238 - $234,732
3,100 Added 4.92%
66,100 $5.01 Billion
Q2 2019

Apr 05, 2024

BUY
$65.7 - $83.98 $197,100 - $251,940
3,000 Added 5.0%
63,000 $4.58 Billion
Q1 2019

Apr 05, 2024

SELL
$77.14 - $90.79 $323,988 - $381,318
-4,200 Reduced 6.54%
60,000 $4.84 Billion
Q4 2018

Apr 05, 2024

SELL
$77.85 - $96.01 $669,510 - $825,686
-8,600 Reduced 11.81%
64,200 $5.92 Billion
Q3 2018

Apr 05, 2024

BUY
$88.91 - $98.84 $640,152 - $711,648
7,200 Added 10.98%
72,800 $6.89 Billion
Q2 2018

Apr 05, 2024

BUY
$89.78 - $106.23 $1.82 Million - $2.16 Million
20,300 Added 44.81%
65,600 $6.08 Billion
Q1 2018

Apr 05, 2024

SELL
$92.01 - $123.21 $202,422 - $271,062
-2,200 Reduced 4.63%
45,300 $4.29 Billion
Q4 2017

Apr 05, 2024

BUY
$89.56 - $98.21 $438,844 - $481,228
4,900 Added 11.5%
47,500 $4.59 Billion
Q3 2017

Apr 05, 2024

BUY
$69.85 - $89.22 $139,700 - $178,440
2,000 Added 4.93%
42,600 $3.79 Billion
Q2 2017

Apr 05, 2024

SELL
N/A
-2,300 Reduced 5.36%
40,600 $2.94 Billion
Q1 2017

Apr 05, 2024

BUY
N/A
4,500 Added 11.72%
42,900 $2.8 Billion
Q4 2016

Apr 05, 2024

BUY
N/A
3,500 Added 10.03%
38,400 $2.4 Billion
Q3 2016

Apr 05, 2024

BUY
N/A
1,800 Added 5.44%
34,900 $2.2 Billion
Q2 2016

Apr 05, 2024

BUY
N/A
3,100 Added 10.33%
33,100 $2.05 Billion
Q1 2016

Apr 05, 2024

SELL
N/A
-3,000 Reduced 9.09%
30,000 $1.71 Billion
Q3 2015

Apr 05, 2024

SELL
N/A
-3,000 Reduced 8.33%
33,000 $1.8 Billion
Q2 2015

Apr 05, 2024

BUY
N/A
2,700 Added 8.11%
36,000 $2.42 Billion
Q4 2014

Apr 05, 2024

SELL
N/A
-2,400 Reduced 6.72%
33,300 $2.21 Billion
Q2 2014

Apr 05, 2024

SELL
N/A
-2,700 Reduced 7.03%
35,700 $2.01 Billion
Q4 2013

Apr 05, 2024

SELL
N/A
-2,100 Reduced 5.19%
38,400 $2.04 Billion
Q3 2013

Apr 05, 2024

BUY
N/A
3,000 Added 8.0%
40,500 $1.81 Billion
Q2 2013

Apr 05, 2024

SELL
N/A
-5,700 Reduced 13.19%
37,500 $1.55 Billion
Q1 2013

Apr 05, 2024

BUY
N/A
43,200
43,200 $1.76 Billion

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $348B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track E. Ohman J:Or Asset Management Ab Portfolio

Follow E. Ohman J:Or Asset Management Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of E. Ohman J:Or Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on E. Ohman J:Or Asset Management Ab with notifications on news.